Monoclonal antibody (mAb)-based therapies have revolutionized cancer treatment; however, their clinical efficacy is often limited by insufficient antibody-dependent cellular cytotoxicity (ADCC), tumor antigen escape, and an immunosuppressive tumor microenvironment (TME). To overcome these limitations, we developed an a...
Yan-Ruide Li, Yi-Chen Zhu, Yan-Qi Yu et al.· Cancer immunology research· 0 citations
BACKGROUND
Mucosal-associated invariant T (MAIT) cells are innate-like T lymphocytes that recognize riboflavin-derived metabolites presented by the monomorphic major histocompatibility complex (MHC)-class I-related molecule MR1. MAIT cells are highly enriched in the human liver and are increasingly implicated in liver...
Yan-Ruide Li, Xin-Yuan Shen, Yi-Chen Zhu et al.· i Medicina· 1 citation
CD16HSC-NKT cells are established as a versatile and scalable cellular platform that synergizes with cusatuzumab to enhance therapeutic efficacy against RCC, and represent a promising approach to overcoming current limitations of monoclonal antibody therapy and advancing next-generation immunotherapies for solid tumors...
Yan-Ruide Li, Yi-Chen Zhu, Yu-Ning Chen et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.